---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-047189"
form_type: "8-K/A"
ticker: "AIXC"
cik: "0001460702"
company_name: "AIxCrypto Holdings, Inc."
filed_at: "2024-11-21T23:59:59+00:00"
generated_at: "2026-05-29T20:36:56.748268+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Qualigen Therapeutics appoints Graydon Bensler as independent director and audit committee chair

## Summary
- Bensler appointed to Board effective Nov 7, 2024; named audit committee chair on Nov 21.
- Director Agreement provides $5,000 monthly base fee plus eligibility for equity awards and indemnification.
- Bensler is independent under Nasdaq rules; amendment corrects prior 8-K with proper agreement.
- Appointment fills Board vacancy and strengthens audit committee oversight.

## SEC filing metadata
- accession: 0001493152-24-047189
- form_type: 8-K/A
- ticker: AIXC
- cik: 0001460702
- company_name: AIxCrypto Holdings, Inc.
- filed_at: 2024-11-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1460702/000149315224047189/0001493152-24-047189-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1460702/000149315224047189/form8-ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-047189
- JSON: https://secwatch.observer/filing/0001493152-24-047189.json
- Plain text: https://secwatch.observer/filing/0001493152-24-047189.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.